- Home
- SNTI vs PLUR Comparison
SNTI vs PLUR Comparison
Compare SNTI & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- PLUR
- Stock Information
- Founded
- SNTI 2016
- PLUR 2001
- Country
- SNTI United States
- PLUR Israel
- Employees
- SNTI N/A
- PLUR N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNTI Health Care
- PLUR Health Care
- Exchange
- SNTI Nasdaq
- PLUR Nasdaq
- Market Cap
- SNTI 21.3M
- PLUR 24.9M
- IPO Year
- SNTI N/A
- PLUR N/A
- Fundamental
- Price
- SNTI $3.96
- PLUR $4.33
- Analyst Decision
- SNTI Strong Buy
- PLUR
- Analyst Count
- SNTI 1
- PLUR 0
- Target Price
- SNTI $12.00
- PLUR N/A
- AVG Volume (30 Days)
- SNTI 30.3K
- PLUR 6.8K
- Earning Date
- SNTI 03-20-2025
- PLUR 02-11-2025
- Dividend Yield
- SNTI N/A
- PLUR N/A
- EPS Growth
- SNTI N/A
- PLUR N/A
- EPS
- SNTI N/A
- PLUR N/A
- Revenue
- SNTI N/A
- PLUR $678,000.00
- Revenue This Year
- SNTI $11.52
- PLUR N/A
- Revenue Next Year
- SNTI $78.57
- PLUR N/A
- P/E Ratio
- SNTI N/A
- PLUR N/A
- Revenue Growth
- SNTI N/A
- PLUR 89.92
- 52 Week Low
- SNTI $1.52
- PLUR $4.07
- 52 Week High
- SNTI $16.94
- PLUR $8.48
- Technical
- Relative Strength Index (RSI)
- SNTI 45.36
- PLUR 45.34
- Support Level
- SNTI $3.92
- PLUR $4.45
- Resistance Level
- SNTI $4.50
- PLUR $4.78
- Average True Range (ATR)
- SNTI 0.26
- PLUR 0.20
- MACD
- SNTI -0.03
- PLUR 0.01
- Stochastic Oscillator
- SNTI 20.59
- PLUR 17.86
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.